The upregulated expression of PD-L1 in GBM cells post-OM-100 treatment indicated a potential mechanism whereby the device might modulate immune responses, thereby rendering GBM cells more receptive to anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is glioblastoma.